IZIsmail Zengin

Ismail Zengin

*This is an algorithmically generated author record based on publicly available information.

Ismail Zengin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Meme Kanserinde Oksidatif Stresin Prognostik Değeri ve Önemi

    by İsmail Zengi̇n, Havva Belma Koçer, Tayfur Demi̇ray, Kerem Yilmaz

    Objective: The aims of this study were to investigate Total Antioxidative Status (TAS), Total Oxidative Status (TOS), and Oxidative Stress Index (OSI) levels in breast cancer patients and compare them to levels in healthy women.Materials and Methods: In the study, 45 breast cancer patients and 46 healthy women participated. The OSI value was calculated as the % ratio of the TAS and TOS values. The data were analyzed on IBM SPSS 21.0 package software.Results: When the mean TOS values in patients and healthy women were compared, the control group had a TOS of 3.44 µ mIU/L and the patient group had a TOS of 11.93 µ mIU/L. TAS was found to have a mean value of 1.74 µ mIU/L in the control group and 1.63 m/mol/L in the patient group. OSI was determined to have a mean value of 7.23 in patients with breast cancer and 1.99 in healthy women. In female patients with breast cancer, TOS value was higher, TAS value was lower, and OSI value was significantly higher than healthy women (p<0.01).Conclusion: TOS, TAS and OSI values ​​can be a marker that can be used to differentiate patients with breast cancer and healthy women.


  • Open Access

    Coexistence of Neurofibromatosis Type 1 and Male Breast Cancer

    by Baris Mantoglu, Burak Kamburoglu, Ismail Zengin, Kayhan Ozdemir, Ebru Kayra, Emre Gonullu, Fatih Altintoprak, Belma Kocer

    Breast cancer is one of the rarest types of cancer in men. Its incidence increases with age, as in women. Neurofibromatosis type 1 is an autosomal dominant genetic disease that predisposes to many cancer types. Neurofibromatosis and breast cancer have been more frequently distinguished and better studied in women. Characteristically, estrogen, progesterone receptors, negative, and overexpression of human epidermal growth factor receptor 2 (HER2) are detected in patients with female neurofibromatosis breast cancers. In cases reported so far, estrogen and progesterone receptors have been evaluated as positive and HER2 negative in male patients. With the high possibility of breast cancer development in female patients with neurofibromatosis at an earlier age, prompt and careful evaluation is required in terms of both examination and radiological imaging. Unfortunately, there are no thorough recommendations for breast cancer follow-up in male patients with neurofibromatosis. Here, we present a breast cancer, which is an uncommon type of cancer in male neurofibromatosis.